Ulrik B. Nielsen
InvestorFounderGeneral Partner at Mission Biocapital · Board director at Alloy Therapeutics, Inc.
Cambridge
Writes $500K checks
About
Ulrik B. Nielsen is an oncology therapeutics founder-turned-investor who led Merrimack to IPO and FDA approval, led Torque and Tidal (acquired by Sanofi), and pioneered in vivo mRNA T‑cell reprogramming.
Invests in
AgTechBiotechFoodTechHealthtechMedical DevicesNew Materials
Board director at Alloy Therapeutics, Inc.
Intro paths
→
In turn, Ulrik can intro founders to Alloy Therapeutics, Inc.'s investors below.
Alloy Therapeutics, Inc.'s investors · 5
Co-founders at Alloy Therapeutics, Inc.
EB
Errik B. AndersonExecutive Officer, Director
Deals · 1
Alloy Therapeutics, Inc.Board seat
via Mission Biocapital · filed Apr 2026 · $40M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Mission Biocapital
Cassidy Blundell
Partner at Mission Biocapital
Chaya Patel
Principal at Mission Biocapital
Chris Carlin
Chief Operations Officer and Chief Compliance Officer at Mission Biocapital
Clay Rowland
Investment Associate at Mission Biocapital
Douglas Crawford
Managing General Partner at Mission Biocapital
Helen Siaw
Analyst at Mission Biocapital
Jennifer Griffin
Partner at Mission Biocapital
Johannes Fruehauf
General Partner at Mission Biocapital
Frequently asked questions
- Who is Ulrik B. Nielsen?
- Ulrik B. Nielsen is an oncology therapeutics founder-turned-investor who led Merrimack to IPO and FDA approval, led Torque and Tidal (acquired by Sanofi), and pioneered in vivo mRNA T‑cell reprogramming.
- Where does Ulrik B. Nielsen work?
- Ulrik B. Nielsen is General Partner at Mission Biocapital and Board director at Alloy Therapeutics, Inc..
- What does Ulrik B. Nielsen invest in?
- Ulrik B. Nielsen invests in AgTech, Biotech, FoodTech, Healthtech, Medical Devices, New Materials.
- What check size does Ulrik B. Nielsen write?
- Ulrik B. Nielsen typically writes checks of $500K.
- What boards does Ulrik B. Nielsen sit on?
- Ulrik B. Nielsen holds tracked board seats at Alloy Therapeutics, Inc..